구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells) Second Affiliated Hospital, School…·EGFR 1 trials |
|---|---|
Overview Program | Metabolically Armed EGFRvIII CAR-T cells |
Overview Company | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Glioblastoma (GBM) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.. Glioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-line therapy. We p… |
Clinical Safety signal | Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.. Glioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-line therapy. We p… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells) Second Affiliated Hospital, School…·EGFR 1 trials |
|---|---|
Overview Program | Metabolically Armed EGFRvIII CAR-T cells |
Overview Company | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Overview Modality | CGT |
Overview Target | EGFR |
Overview Indication | Glioblastoma (GBM) |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.. Glioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-line therapy. We p… |
Clinical Safety signal | Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM.. Glioblastoma (GBM) remains a deadly cancer with non-curative upfront treatment of radiation, resection, and chemotherapy. Not only has the standard of care for GBM patients not improved significantly over the past decade, life expectancy is less than 18 months, with no standard second-line therapy. We p… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교